Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Clinical trial NCT00596804 · COMPLETED

Trial details

NCT number: NCT00596804
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Hodgkin's Lymphoma Lymphoma, Diffuse Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic

Start date: 2004-03-01
Primary completion: 2007-11-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.